Wikipedia -WSS

Wikipedia

author：comprehensive 2025-08-23 18:37:27 - browse：6

A phone screen displays the webpage of Medicare.gov — coverage from STAT — Adobe

Over the past few weeks, Medicare Advantage insurers demanded that the Biden administration give them higher payment rates for next year. The government’s data on how much people were using health care didn’t match their own data, insurers and lobbyists griped — and therefore they wouldn’t be paid enough to cover those costs.

But the federal government was not persuaded by the industry’s data or lobbying push. The Biden administration and its Medicare agency decided to stick with their proposals from January on Monday, dealing a blow to an insurance industry that has come to rely on Medicare Advantage for a steady stream of profits.

The result: In 2025, right after a new president is elected, Medicare Advantage insurers will have to absorb a slight decrease of 0.2% to the baseline payment rates that insurers receive from the government for enrolling older adults and people with disabilities. The stock prices of the largest Medicare Advantage insurers — UnitedHealth, Humana, CVS Health, and Elevance Health — all fell by at least 4% in after-hours trading.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： FDA poised to publish guidelines for clinical trial diversity

explore

WSS

How the first Native Hawaiian psychiatrist helped diversify medicine

CDC says it’s too soon to assess risk posed by Covid subvariant

People can get long Covid without testing positive for virus: Study

Wegovy improves function in certain heart failure patients

Trans patients at the end of life deserve respect and dignity

Questions and answers about ramping up H5N1 bird flu vaccine

hotspot

Wikipedia

entertainment

Duchenne breakthrough therapy leaves behind pioneering families

Study: Spinal cord stimulation helps patients with paralysis walk again

Hollywood unions extend contract negotiations for actors

FDA advisory panel to debate high blood pressure devices

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

BioMarin wins approval for gene therapy to treat hemophilia A

PBMs are inflating the cost of generic drugs. They must be reined in

Alkermes shareholders re

As a primary care physician, here's how I hope to partner with AI

knowledge

Reports of telehealth's death have been greatly exaggerated

Investigation reveals sickle cell patients pressured into sterilizations

Kellogg’s is going to war over Mexico’s nutrition label rules

Meadows told special counsel he could not recall Trump ever declassifying Mar

FDA greenlights medical device to combat bladder issues

How the drug

Wikipedia

entertainment

explore

leisure time